Shots:
PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics.
The report tracks the rise and fall of leading biopharma companies over two decades driven by…
Shots:
Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3B (~$3B), receiving CHF 1.7B (~$2.2B) upfront while retaining a 40% stake with preferential participation in future exit proceeds
Lonza is expecting total undiscounted proceeds of ≥CHF 3B (~$4B) from CHI via…

